Supplementary Figures 1-8 from Vorinostat and Sorafenib Increase CD95 Activation in Gastrointestinal Tumor Cells through a Ca&lt;sup&gt;2+&lt;/sup&gt;-&lt;i&gt;De novo&lt;/i&gt; Ceramide-PP2A-Reactive Oxygen Species–Dependent Signaling Pathway